 Agios Pharmaceuticals Inc NASDAQ: AGIO reported new data from the ongoing long-term extension study assessing the duration of effects of mitapivat in adults with pyruvate kinase PK deficiency. Data were featured at the American Society of Hematology ASH Annual Meeting and Exposition. 